Airsupra is a drug owned by Astrazeneca Pharmaceuticals Lp. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 28, 2030. Details of Airsupra's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9415009 | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Airsupra's patents.
Latest Legal Activities on Airsupra's Patents
Given below is the list of recent legal activities going on the following patents of Airsupra.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Jan, 2024 | US9415009 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Jan, 2020 | US9415009 |
| Post Issue Communication - Certificate of Correction | 14 Apr, 2017 | US9415009 |
| Patent Issue Date Used in PTA Calculation Critical | 16 Aug, 2016 | US9415009 |
| Recordation of Patent Grant Mailed Critical | 16 Aug, 2016 | US9415009 |
| Issue Notification Mailed Critical | 27 Jul, 2016 | US9415009 |
| Dispatch to FDC | 19 Jul, 2016 | US9415009 |
| Issue Fee Payment Received Critical | 01 Jul, 2016 | US9415009 |
| Issue Fee Payment Verified Critical | 01 Jul, 2016 | US9415009 |
| Mail Notice of Allowance Critical | 27 Jun, 2016 | US9415009 |
FDA has granted several exclusivities to Airsupra. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Airsupra, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Airsupra.
Exclusivity Information
Airsupra holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Airsupra's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 10, 2026 |
US patents provide insights into the exclusivity only within the United States, but Airsupra is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Airsupra's family patents as well as insights into ongoing legal events on those patents.
Airsupra's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Airsupra's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 28, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Airsupra Generics:
There are no approved generic versions for Airsupra as of now.
About Airsupra
Airsupra is a drug owned by Astrazeneca Pharmaceuticals Lp. It is used for the treatment and prevention of bronchoconstriction and reduction of exacerbation risk in patients with asthma. Airsupra uses Albuterol Sulfate; Budesonide as an active ingredient. Airsupra was launched by Astrazeneca in 2023.
Approval Date:
Airsupra was approved by FDA for market use on 10 January, 2023.
Active Ingredient:
Airsupra uses Albuterol Sulfate; Budesonide as the active ingredient. Check out other Drugs and Companies using Albuterol Sulfate; Budesonide ingredient
Treatment:
Airsupra is used for the treatment and prevention of bronchoconstriction and reduction of exacerbation risk in patients with asthma.
Dosage:
Airsupra is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.09MG BASE/INH;0.08MG/INH | AEROSOL, METERED | Prescription | INHALATION |